HANSOH PHARMA (03692) announced its interim results, with a profit attributable to shareholders of 4.258 billion yuan, an increase of 35.82% compared to the same period last year.

HANSOH PHARMA (03692) announced its interim results for the six months ending June 30, 2026, during which the group achieved a revenue of RMB 8.304 billion, an increase of 11.71% compared to the same period last year; the profit attributable to shareholders amounted to RMB 4.258 billion, up 35.82% year-on-year; earnings per share stood at RMB 0.7, with a proposed interim dividend of HKD 0.285 per share. The announcement stated that the increase in profit and basic earnings per share during the reporting period was primarily attributed to the rise in revenue from innovative drugs and the increase in other income. As of June 30, 2026, the group had over seventy ongoing clinical trials for innovative drugs, covering more than forty candidate innovative drugs.